Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272766 · ClinicalTrials.gov registry record · NA
Macugen for Histoplasmosis
A NA study, sponsored by Barnes Retina Institute.
- Terminated
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00272766 is a NA study that was terminated before completion, run by Barnes Retina Institute. The registered enrollment target is 24 participants.
The verdict
NCT00272766, a NA study, was terminated before completion, sponsored by Barnes Retina Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).
Interventions
- DRUG pegaptanib sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00272766
The ClinicalTrials.gov registry entry for NCT00272766 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barnes Retina Institute, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pegaptanib sodium is the first listed.
NCT00272766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00272766 about?
NCT00272766 is a clinical study titled "Macugen for Histoplasmosis". The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).
What is the current status of trial NCT00272766?
This trial is currently terminated. It is a NA study. The enrollment target is 24 participants. The study started on 2006-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00272766?
The interventions under investigation include: pegaptanib sodium (DRUG).
Who is sponsoring clinical trial NCT00272766?
This trial is sponsored by Barnes Retina Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.